Donald E. O'Neill has been elected chairman of NovaPharmaceutical Corp., succeeding John Lloyd Huck, who willremain as a director. O'Neill was executive vice president andchairman of international operations for Warner-Lambert Co.until his retirement this year. Baltimore-based NovaPharmaceutical (NASDAQ:NOVX) is focused on treatments forcentral nervous system disorders and inflammation.
Dr. Alex McPherson has been appointed president and chiefexecutive officer of Biomira Inc. of Edmonton, Alberta, adeveloper of cancer treatments and diagnostics. McPherson is aformer deputy minister of Alberta Hospitals and Medical Careand is past president of both the Alberta and Canadian medicalassociations.
Oncogene Science Inc. has promoted J. Gordon Foulkes to vicepresident and chief scientific officer, and John M. Sorvillo tovice president and director of research, research products anddiagnostics. Foulkes had been director of therapeutic productdevelopment and Sorvillo senior research scientist. Oncogene(NASDAQ:ONCS) of Uniondale, N.Y., is developing products forthe treatment and diagnosis of diseases associated withabnormalities of cell growth and control.
Chiron Corp. (NASDAQ:CHIR) of Emeryville, Calif., has namedWalter H. Moos, Ph.D., vice president of research anddevelopment for chemical therapeutics. Moos was chairman ofthe Parke-Davis scientific advisory committee of the Warner-Lambert/Chiron/Protos collaboration to develop treatmentsfor central nervous system disorders and cancer.
Iomed Inc., a Salt Lake City drug delivery systems company,has elected Ned M. Weinshenker, Ph.D., as chairman.Weinshenker, president of Churchill Oaks Consulting of PaloAlto, Calif., had been a director. The company also namedThomas Michael Parkinson, Ph.D., vice president for researchand development. Parkinson was vice president for clinicaldevelopment and regulatory affairs at Liposome TechnologyInc.
(c) 1997 American Health Consultants. All rights reserved.